The VESALIUS-CV trial, presented at ACC 2026, investigated the effect of evolocumab on reducing cardiovascular events. Patients with diabetes who did not have known atherosclerosis were included in the study. The aim was to determine whether evolocumab reduces the risk of first serious cardiovascular events in this group of patients. The results of the study were published in JAMA. The publication also includes an editorial that deals with the questions of when, in whom and how to reduce lipids. The VESALIUS-CV study focuses on patients with diabetes without known atherosclerosis.